First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease

Gastroesophageal Reflux Disease (GERD)

Comparison of Laparoscopic 270° Posterior Partial Fundoplication vs Total Fundoplication for the Treatment of Gastroesophageal Reflux Disease: A Randomized Clinical Trial

JAMA Surg.

Håkanson BS, Lundell L, Bylund A, Thorell A

doi: 10.1001/jamasurg.2019.0047.

Esophagus DiseasesGastroesophageal Reflux Disease (GERD)

Novel Surgical Treatments for Gastroesophageal Reflux Disease: Systematic Review of Magnetic Sphincter Augmentation and Electric Stimulation Therapy

Gastroenterology Res.

Stanak M, Erdos J, Hawlik K, Birsan T

doi: 10.14740/gr1024w.

Gastroesophageal Reflux Disease (GERD)

Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders

Clin Rev Allergy Immunol.

Hait EJ, McDonald DR

doi: 10.1007/s12016-018-8701-4.

Inflammatory Bowel Disease

Cannabis for the treatment of Crohn's disease

Cochrane Database Syst Rev.

Kafil TS, Nguyen TM, MacDonald JK, Chande N

doi: 10.1002/14651858.

Gastroesophageal Reflux Disease (GERD)

The Reflux Improvement and Monitoring (TRIM) Program Is Associated With Symptom Improvement and Weight Reduction for Patients With Obesity and Gastroesophageal Reflux Disease

Am J Gastroenterol.

Yadlapati R, Pandolfino JE, Alexeeva O, Gregory DL, Craven MR, Liebovitz D, Lichten A, Seger E, Workman M, St Peter N, Craft J, Doerfler B, Keswani RN

doi: 10.1038/ajg.2017.262.

Gastroesophageal Reflux Disease (GERD)

Mucosal Impedance: a New Approach to Diagnosing Gastroesophageal Reflux Disease and Eosinophilic Esophagitis

Curr Gastroenterol Rep.

Barrett C, Choksi Y, Vaezi MF

doi: 10.1007/s11894-018-0639-4.

Inflammatory Bowel Disease

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Lancet Gastroenterol Hepatol.

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group

doi: 10.1016/S2468-1253(19)30012-3.

Gastroesophageal Reflux Disease (GERD)

Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis

Endoscopy.

McCarty TR, Itidiare M, Njei B, Rustagi T

doi: 10.1055/a-0576-6589.

Inflammatory Bowel Disease

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

United European Gastroenterol J.

Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A

doi: 10.1177/2050640619873784.

Related content

Comparison of Laparoscopic 270° Posterior Partial Fundoplication vs Total Fundoplication for the Treatment of Gastroesophageal Reflux Disease: A Randomized Clinical Trial

Novel Surgical Treatments for Gastroesophageal Reflux Disease: Systematic Review of Magnetic Sphincter Augmentation and Electric Stimulation Therapy

Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders

Cannabis for the treatment of Crohn's disease

The Reflux Improvement and Monitoring (TRIM) Program Is Associated With Symptom Improvement and Weight Reduction for Patients With Obesity and Gastroesophageal Reflux Disease

Mucosal Impedance: a New Approach to Diagnosing Gastroesophageal Reflux Disease and Eosinophilic Esophagitis

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease